JH-RE-06-d6 is a deuterium-labeled version of JH-RE-06, a potent REV1-REV7 interface inhibitor. It has an IC50 of 0.78 μM and a Ki of 0.42 μM, targeting REV1, which interacts with the REV7 subunit of POLζ. This compound works by disrupting mutagenic translesion synthesis (TLS) through preventing the recruitment of mutagenic POLζ, and has been shown to improve chemotherapy. It is intended for research use only and is not sold to patients.
- Potent REV1-REV7 interface inhibitor
- Targets REV1, interacting with the REV7 subunit of POLζ
- Disrupts mutagenic translesion synthesis (TLS)
- Prevents recruitment of mutagenic POLζ
- Improves chemotherapy
- Deuterium-labeled
- Can be used as a tracer
- Can be used as an internal standard for quantitative analysis by NMR, GC-MS, or LC-MS